Browse > Article

Significant Mismatch between FDG Uptake and Size after Chemotherapy in a Patient with Non-small Cell Lung Cancer  

Kwon, Seong-Young (Department of Nuclear Medicine, Chonnam National University Medical School)
Jeong, Shin-Young (Department of Nuclear Medicine, Chonnam National University Medical School)
Seo, Young-Soon (Department of Nuclear Medicine, Chonnam National University Medical School)
Ha, Jung-Min (Department of Nuclear Medicine, Chonnam National University Medical School)
Chong, A-Ri (Department of Nuclear Medicine, Chonnam National University Medical School)
Oh, Jong-Ryool (Department of Nuclear Medicine, Chonnam National University Medical School)
Song, Ho-Chun (Department of Nuclear Medicine, Chonnam National University Medical School)
Min, Jung-Joon (Department of Nuclear Medicine, Chonnam National University Medical School)
Bom, Hee-Seung (Department of Nuclear Medicine, Chonnam National University Medical School)
Publication Information
Nuclear Medicine and Molecular Imaging / v.42, no.6, 2008 , pp. 488-490 More about this Journal
Abstract
A 75-year-old man with non-small cell lung cancer (NSCLC) underwent F-18 fluorodeoxyglucose (FDG) PET/CT for staging. PET/CT showed distant metastases to intra-abdominal lymph nodes (LNs) as well as bilateral mediastinal LNs (stage IV), He underwent PET/CT (restaging PET/CT) 1week after the completion of first-line chemotherapy (docetaxel+carboplatin). It showed markedly increased FDG uptake in primary tumor, whereas tumor size decreased significantly, compared to prior PET/CT. This lesion was aggravated on follow-up CT 3 months after the completion of chemotherapy. Although there are several reports that FDG PET has potential to evaluate early response to chemotherapy and prognosis, there are a few cases to show mismatch between FDG uptake and size on PET/CT. Thus we report a case of NSCLC showed increased FDG uptake of primary tumor while decreased tumor size on restaging PET/CT.
Keywords
Non-small cell lung cancer; mismatch; FDG; size;
Citations & Related Records
연도 인용수 순위
  • Reference
1 De Geus-Oei LF, van der Heijden HF, Visser EP, Hermsen R, van Hoorn BA, Timmer-Bonte JN, et al. Chemotherapy response evaluation with $^{18}F-FDG$ PET in patients with non-small cell lung cancer. J Nucl Med 2007;48:1592-8   DOI
2 Di Paolo A, Bocci G. Drug distribution in tumors: mechanisms, role in drug resistance, and methods for modification. Curr Oncol Rep 2007;9:109-14   DOI   ScienceOn
3 Wyss MT, Honer M, Schubiger PA, Ametamey SM. NanoPET imaging of [$^{18}F$] fluoromisonidazole uptake in experimental mouse tumours. Eur J Nucl Med Mol Imaging 2006;33:311-8   DOI
4 Mankoff DA, Dunnwald LK, Gralow JR, Ellis GK, Charlop A, Lawton TJ, et al. Blood flow and metabolism in locally advanced breast cancer: relationship to response to therapy. J Nucl Med 2002;43:500-9
5 Gottesman MM, Fojo T, Bates SE. Multidrug resistance in cancer: role of ATP dependent transporters. Nat Rev Cancer 2002;2:48-58   DOI   ScienceOn
6 Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92:205-16   DOI   ScienceOn
7 Nahmias C, Hanna WT, Wahl LM, Long MJ, Hubner KF, Townsend DW. Time course of early response to chemotherapy in non-small cell lung cancer patients with $^{18}F-FDG$ PET/CT. J Nucl Med 2007;48:744-51   DOI
8 Tanaka T, Furukawa T, Fujieda S, Kasamatsu S, Yonekura Y, Fujibayashi Y. Double-tracer autoradiography with Cu-ATSM/FDG and immunohistochemical interpretation in four different mouse implanted tumor models. Nucl Med Biol 2006;33:743-50   DOI   ScienceOn
9 Cerfolio RJ, Bryant AS, Winokur TS, Ohja B, Bartolucci AA. Repeat FDG-PET after neoadjuvant therapy is a predictor of pathologic response in patients with non-small cell lung cancer. Ann Thorac Surg 2004;78:1903-9   DOI   ScienceOn
10 Gu J, Yamamoto H, Fukunaga H, Danno K, Takemasa I, Ikeda M, et al. Correlation of GLUT-1 overexpression, tumor size, and depth of invasion with $^{18}F-2-fluoro-2-deoxy-D-glucose$ uptake by positron emission tomography in colorectal cancer. Dig Dis Sci 2006;51: 2198-205   DOI
11 Kannan S. Free radical theory of autoimmunity. Theor Biol Med Model 2006;7:3-22
12 Hoekstra CJ, Hoekstra OS, Stroobants SG, Vansteenkiste J, Nuyts J, Smit EF et al. Methods to monitor response to chemotherapy in non-small cell lung cancer with $^{18}F-FDG$ PET. J Nucl Med 2002;43:1304-9
13 Zanzonico P, Campa J, Polycarpe-Holman D, Forster G, Finn R, Larson S, et al. Animal-specific positioning molds for registration of repeat imaging studies: comparative microPET imaging of $^{18}F-labeled$ fluoro-deoxyglucose and fluoro-misonidazole in rodent tumors. Nucl Med Biol 2006;33:65-70   DOI   ScienceOn